Patients maintained these responses after 52 weeks of treatment with tralokinumab without any rescue medication.49, 55 Lebrikizumab, a mAb that targets IL-13 in two randomized, double-blind, placebo-controlled, phase 3 trials in >12-years old patients with moderate to severe AD showed an EASI-75 response in 58.8% and 52.1% of patients respectively at week 16.56 Here, IL13 is linked to Alzheimer disease.